Business Context and Reporting Period
This Form 8-K, dated February 27, 2020, is filed by Landec Corporation (LNDC), a diversified health and wellness company with two operating segments: Curation Foods, Inc. and Lifecore Biomedical, Inc. The filing discloses a strategic initiative to explore alternatives, including potential divestiture, for Curation Foods' legacy vegetable bag and tray business. This action is part of "Project SWIFT," a shareholder value creation program aimed at simplifying operations and improving profitability.
Key Financial Metrics and Guidance
The filing provides updated financial guidance for fiscal year 2020 and the third quarter of 2020, excluding restructuring and non-recurring charges. Historical data indicates the legacy vegetable bag and tray business generated $160 million in net sales for fiscal year 2019.
| Metric | Fiscal Year 2020 Guidance | Fiscal Q3 2020 Guidance |
|---|---|---|
| Revenues (Continuing Operations) | $580 million to $590 million (4% to 6% growth vs. FY2019) | $147 million to $151 million |
| Earnings Per Share (EPS) | $0.16 to $0.20 | $0.02 to $0.06 |
| Consolidated EBITDA | $30 million to $34 million | $5 million to $9 million |
Long-Term Targets (Curation Foods by end of FY2021):
- Organic Revenue Growth: 5%
- Gross Margin: 11% to 14%
- EBITDA Margin: 4% to 6%
Cost Savings: Project SWIFT anticipates annualized cost savings of $5.0 million upon full implementation.
Material Changes and Strategic Actions
Management has lowered full fiscal year 2020 and third-quarter 2020 guidance. The reduction accounts for an acceleration in the planned reduction of the vegetable bag and tray business, unanticipated legal fees, and incremental marketing spending for the Yucatan Squeeze innovation. Additionally, Lifecore Biomedical is shifting revenue timing from the third quarter to the fourth quarter, though it remains on target for full-year goals. The company has engaged William Blair to identify strategic alternatives for the legacy business, though no assurance of a transaction is provided.
Outlook, Risks, and Management Commentary
CEO Dr. Albert Bolles stated the strategy involves "getting smaller to get bigger" by rightsizing the legacy business to focus on higher-margin product platforms. The company expects to see normalized margins in the Yucatan business in the fourth quarter following lean manufacturing implementation. Key risks include the timing and success of the divestiture process, market acceptance of new products, weather conditions affecting produce supply, and regulatory approvals. The filing includes standard forward-looking statement disclaimers regarding uncertainties in operations and integration.
Investor Verification Checklist
- Verify the status and timeline of the strategic alternatives process for the Curation Foods vegetable bag and tray business.
- Confirm the specific impact of unanticipated legal fees on the revised guidance.
- Monitor the execution of revenue timing shifts between Q3 and Q4 for Lifecore Biomedical.
- Assess the progress of the $5.0 million annualized cost savings target under Project SWIFT.
- Review the integration status and margin normalization of the Yucatan Squeeze innovation.